Free Trial Information
BioCentury | Jun 26, 2020
Politics, Policy & Law

Illumina, BGI litigation not yet at risk of getting drawn into U.S.-China dispute

...report on Chinese activities cited the acquisition as an example of Chinese firms targeting the U.S. genomics...
Read More
BioCentury | Jun 11, 2019
Politics & Policy

Senators call for HHS probe into CMS genetic testing payments to Chinese-linked companies

Sens. Charles Grassley (R-Iowa) and Marco Rubio (R-Fla.) have asked the HHS inspector general to investigate payments made by CMS to U.S. genetic testing companies that are partnered with companies that have ties to Beijing....
Read More
BioCentury | Sep 24, 2012
Finance

Completing genomics

...54% premium to Complete Genomics' June 4 close of $2.04 - the day before the U.S. genomics...
Read More
BioCentury | Sep 29, 2008
Company News

Becton Dickinson, U.S. Genomics deal

...infectious disease detection platform using U.S. Genomics' DirectLinear analysis technology for detecting pathogens in clinical samples. U.S. Genomics...
...a $4.5 million equity investment in U.S. Genomics. Becton Dickinson and Co. (NYSE:BDX), Franklin Lakes, N.J. U.S. Genomics Inc....
Read More
BioCentury | Nov 5, 2007
Clinical News

Oncotype DX regulatory update

GHDX received CE Mark approval for its Oncotype DX to predict the likelihood of breast cancer recurrence and likelihood of chemotherapy benefit for node-negative, estrogen receptor-positive breast cancer patients. The diagnostic assay, which analyzes the...
Read More
BioCentury | Sep 17, 2007
Strategy

Make microlove, not war

...issued patents covering methods of miRNA prediction and validation. Last year, the company partnered with U.S. Genomics Inc....
...Woburn, Mass.) to discover and develop an miRNA-based test for lung cancer. The deal combined U.S. Genomics'...
Read More
BioCentury | May 14, 2007
Company News

U.S. Genomics board of directors update

U.S. Genomics Inc. , Woburn, Mass. Business: Supply/Service, Genomics Appointed: Salvatore Salamone, chairman and CEO of Saladax BioMedical Inc. WIR Staff...
Read More
BioCentury | Feb 5, 2007
Company News

Metabolon management update

...Pharmacogenetics Hired: Tim Germann as VP of sales, formerly VP of sales and marketing at U.S. Genomics Inc....
Read More
BioCentury | Jan 29, 2007
Company News

Quest Diagnostics, U.S. Genomics deal

...fragile X syndrome (FXS). Further terms were not disclosed. Quest Diagnostics Inc. (DGX), Teterboro, N.J. U.S. Genomics Inc....
Read More
BioCentury | Oct 23, 2006
Company News

U.S. Genomics, Lahey Clinic Medical Center deal

...miRNA) in urologic cancers to improve diagnosis of bladder and prostate cancer. The partnership combines U.S. Genomics'...
...the medical center's expertise in the analysis of tumor progression and experience in disease management. U.S. Genomics Inc....
Read More
Items per page:
1 - 10 of 52
BioCentury | Jun 26, 2020
Politics, Policy & Law

Illumina, BGI litigation not yet at risk of getting drawn into U.S.-China dispute

...report on Chinese activities cited the acquisition as an example of Chinese firms targeting the U.S. genomics...
Read More
BioCentury | Jun 11, 2019
Politics & Policy

Senators call for HHS probe into CMS genetic testing payments to Chinese-linked companies

Sens. Charles Grassley (R-Iowa) and Marco Rubio (R-Fla.) have asked the HHS inspector general to investigate payments made by CMS to U.S. genetic testing companies that are partnered with companies that have ties to Beijing....
Read More
BioCentury | Sep 24, 2012
Finance

Completing genomics

...54% premium to Complete Genomics' June 4 close of $2.04 - the day before the U.S. genomics...
Read More
BioCentury | Sep 29, 2008
Company News

Becton Dickinson, U.S. Genomics deal

...infectious disease detection platform using U.S. Genomics' DirectLinear analysis technology for detecting pathogens in clinical samples. U.S. Genomics...
...a $4.5 million equity investment in U.S. Genomics. Becton Dickinson and Co. (NYSE:BDX), Franklin Lakes, N.J. U.S. Genomics Inc....
Read More
BioCentury | Nov 5, 2007
Clinical News

Oncotype DX regulatory update

GHDX received CE Mark approval for its Oncotype DX to predict the likelihood of breast cancer recurrence and likelihood of chemotherapy benefit for node-negative, estrogen receptor-positive breast cancer patients. The diagnostic assay, which analyzes the...
Read More
BioCentury | Sep 17, 2007
Strategy

Make microlove, not war

...issued patents covering methods of miRNA prediction and validation. Last year, the company partnered with U.S. Genomics Inc....
...Woburn, Mass.) to discover and develop an miRNA-based test for lung cancer. The deal combined U.S. Genomics'...
Read More
BioCentury | May 14, 2007
Company News

U.S. Genomics board of directors update

U.S. Genomics Inc. , Woburn, Mass. Business: Supply/Service, Genomics Appointed: Salvatore Salamone, chairman and CEO of Saladax BioMedical Inc. WIR Staff...
Read More
BioCentury | Feb 5, 2007
Company News

Metabolon management update

...Pharmacogenetics Hired: Tim Germann as VP of sales, formerly VP of sales and marketing at U.S. Genomics Inc....
Read More
BioCentury | Jan 29, 2007
Company News

Quest Diagnostics, U.S. Genomics deal

...fragile X syndrome (FXS). Further terms were not disclosed. Quest Diagnostics Inc. (DGX), Teterboro, N.J. U.S. Genomics Inc....
Read More
BioCentury | Oct 23, 2006
Company News

U.S. Genomics, Lahey Clinic Medical Center deal

...miRNA) in urologic cancers to improve diagnosis of bladder and prostate cancer. The partnership combines U.S. Genomics'...
...the medical center's expertise in the analysis of tumor progression and experience in disease management. U.S. Genomics Inc....
Read More
Items per page:
1 - 10 of 52